These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 6541825)

  • 1. Nonsurgical management of patients with stage D1 adenocarcinoma of prostate: risks vs benefits.
    deVere White R
    Urology; 1984 Nov; 24(5 Suppl):12-5. PubMed ID: 6541825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New concepts in the treatment of stage D1 adenocarcinoma of the prostate.
    Austenfeld MS; Davis BE
    Urol Clin North Am; 1990 Nov; 17(4):867-84. PubMed ID: 2219583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Just Another Statistic".
    Machtay M; Glatstein E
    Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adenocarcinoma of the prostate].
    Dvorácek J
    Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy.
    Mayer FJ; Crawford ED
    Urol Clin North Am; 1994 Nov; 21(4):707-15. PubMed ID: 7974899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adjuvant radiotherapy following radical prostatectomy--results, acute and late toxicity].
    Wiegel T; Bressel M; Baumann M; Schwarz R; Hübener KH
    Strahlenther Onkol; 1993 Mar; 169(3):152-8. PubMed ID: 8465249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate.
    Amling CL; Leibovich BC; Lerner SE; Bergstralh EJ; Blute ML; Myers RP; Zincke H
    Semin Urol Oncol; 1997 Nov; 15(4):215-21. PubMed ID: 9421448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic markers in clinically localized prostate cancer.
    Pettaway CA
    Tech Urol; 1998 Mar; 4(1):35-42. PubMed ID: 9568775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy for locally recurrent prostate cancer.
    Kirkpatrick JP; Anscher MS
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):933-42. PubMed ID: 16555435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors].
    Feyaerts A; Delrée A; Lorge F; Opsomer RJ; Wese FX; Van Cangh PJ; Draguet AP; Cosyns JP
    Acta Urol Belg; 1997 Mar; 65(1):11-8. PubMed ID: 9245198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
    Zincke H; Lau W; Bergstralh E; Blute ML
    J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional treatments of localized prostate cancer.
    Zerbib M; Zelefsky MJ; Higano CS; Carroll PR
    Urology; 2008 Dec; 72(6 Suppl):S25-35. PubMed ID: 19095125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Curative treatment of prostatic cancer in Norway in 1998 and 2001].
    Kvåle R; Skarre E; Tønne A; Kyrdalen AE; Norstein J; Angelsen A; Wahlqvist R; Fosså SD
    Tidsskr Nor Laegeforen; 2006 Mar; 126(7):912-6. PubMed ID: 16554883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of advanced prostatic cancer].
    Hedlund PO
    Lakartidningen; 2000 Aug; 97(32-33):3466-9. PubMed ID: 11037588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
    Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
    Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic role of lymphadenectomy in adenocarcinoma of the prostate.
    Paulson DF
    Urol Clin North Am; 1980 Oct; 7(3):615-22. PubMed ID: 7456174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
    Wikström P; Lindahl C; Bergh A
    Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
    Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
    Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.